Recently, China approved its first commercial cell therapy product—marking a major milestone in the country’s biopharmaceutical landscape.
On June 22, the National Medical Products Administration (NMPA) announced the official approval of axicabtagene ciloleucel (brand name: Yikaida). The news immediately pushed cell therapy back into the public spotlight. With patients’ lives at stake and treatment prices running high, people are understandably asking: What exactly is cell therapy? Is it reliable? And how can the public distinguish real scientific progress from misleading claims?
What Is Cell Therapy?
Cell therapy refers to treatments that involve transplanting human (or animal) cells—either from donors or from the patients themselves—after they have been processed outside the body. In simple terms, it is a therapeutic approach that reintroduces living cells into the human body for the purpose of treating, diagnosing, or preventing diseases.
What Is CAR-T Therapy?
CAR-T cell therapy stands for Chimeric Antigen Receptor T-cell therapy, a cutting-edge form of immunotherapy.
Globally, regulatory agencies including the China NMPA and U.S. FDA have approved over 800 clinical trials involving CAR-T treatments, with several products already on the market. The principle is straightforward yet revolutionary:
- T cells are collected from the patient’s blood.
- The cells are genetically engineered to express a chimeric antigen receptor (CAR) that recognizes cancer-specific antigens.
- These engineered CAR-T cells are then infused back into the patient.
- Once inside the body, CAR-T cells track down and destroy cancer cells.
Why is CAR-T cell therapy so expensive?
All currently approved CAR-T therapies are autologous—fully personalized treatments. This makes them time-consuming and costly.
Each therapy must be manufactured individually from a patient’s own cells.
The process takes 2–5 weeks, and patients often require pre-conditioning chemotherapy.
If a patient’s immune system is too weak, obtaining functional T cells can be difficult.
Manufacturing requires extremely high sterility and quality control—each batch is unique, and each batch must undergo rigorous testing.
These factors naturally drive up costs, making autologous CAR-T therapy one of the most complex and expensive cancer treatments available today.
The Future of Cell Therapy: Promising and Accessible
The approval of an autologous cell therapy product is an encouraging step forward. Although current treatment costs remain high, this development offers renewed hope for patients with cancers historically considered “incurable.”
Researchers worldwide are exploring off-the-shelf CAR-T therapies, in which donor-derived T cells—or T cells generated from stem cells—are engineered and stored as ready-to-use products.
If CAR-T no longer requires individualized production, the manufacturing process could be greatly simplified, and costs significantly reduced.
This approach aims to:
- shorten treatment wait times,
- lower production costs,
- offer standardized dosing,
- and make advanced therapy available to more patients.
Beyond CAR-T, other cell therapies are also moving toward off-the-shelf formats. As research and technology continue to advance, more patients with advanced cancers may eventually have treatments that are both effective and affordable.
Cell therapy is still evolving—but its future is filled with possibility.
